How many drugs treat Sneezing?

Drug Landscape tracks 10 marketed treatments for Sneezing (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/sneezing.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sneezing — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sneezing (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sneezing, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Allegra	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25
Zyrtec	cetirizine	Generic (originally UCB Pharma)	Second-generation antihistamine	Angiopoietin-1 receptor, Histamine H1 receptor, Potassium voltage-gated channel subfamily H member 2	1995-09-29
Semprex-D	ACRIVASTINE	Auxilium Pharms Inc	Histamine-1 Receptor Antagonist	Histamine H1 receptor	1994-01-01
Claritin	loratadine	Generic (originally Schering-Plough)	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Phenazoline	ANTAZOLINE	Novartis	antazoline	Histamine H1 receptor	1990-01-01
Hispril	DIPHENYLPYRALINE	GSK	diphenylpyraline	Histamine H1 receptor	1982-01-01
Marezine	CYCLIZINE	GSK	cyclizine	Histamine H1 receptor	1982-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 13 drugs in Sneezing
Generic (multiple manufacturers) · 2 drugs in Sneezing
Bayer · 2 drugs in Sneezing
Novartis · 2 drugs in Sneezing
GSK · 2 drugs in Sneezing
Generic (originally Hoechst Marion Roussel/Sanofi) · 1 drug in Sneezing
Generic (originally Roche) · 1 drug in Sneezing
Generic (originally Schering-Plough) · 1 drug in Sneezing
Generic (originally Schering-Plough/MSD) · 1 drug in Sneezing
Generic (originally UCB Pharma) · 1 drug in Sneezing
Impax Labs · 1 drug in Sneezing
Max Zeller Soehne AG · 1 drug in Sneezing

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sneezing:

Cite this brief

Drug Landscape (2026). Sneezing — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sneezing. Accessed 2026-06-10.

Sneezing full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing